Pervasis Therapeutics Inc., a Cambridge, Mass.-based developer of regenerative cell-based therapies and devices, has raised $9.75 million in Series B-1 funding. Return backers include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.
PRESS RELEASE
Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced that it has secured $9.75 million in additional financing through Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.
The new investment will support further development of Pervasis' innovative Vascugel
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.